TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04636658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometer training
Description: Incentive spirometer training 5 sessions a week, each session of 15 minutes, for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic resistance exercises
Description: Incentive spirometer with diaphragmatic resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient.~Digital spirometer training for 15 minutes. diaphragm breathing exercises with resistance for 30 minutes. 5 sessions a week, for 4 weeks
Study: NCT03911648

Intervention type: DRUG
Intervention: 0.5 ml.kg-1 bupivacaine 0.25%
Description: Caudally

Intervention type: DRUG
Intervention: 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1%
Description: Caudally
Study: NCT01701414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral nerve block: 25 mL of 0.5% bupivacaine
Description: 25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
Study: NCT04301063

Intervention type: OTHER
Intervention: RV3278A
Description: RV3278A is a non-rinsed cosmetic cream intended to be used every day on adolescents and young adults with acne-prone skin.
Study: NCT01701414

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo: 3cc of 0.9% Normal Saline
Description: 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
Study: NCT01758835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint 3 weeks
Description: A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cast 3 weeks
Description: A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cast 6 weeks
Description: standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
Study: NCT04214548

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT01217476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trafermin 0.01% spray
Description: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
Study: NCT02037191

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day
Study: NCT04290715

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03567005

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A digital contact lenses
Description: Silicone hydrogel digital contact lenses
Study: NCT00262769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
Study: NCT04890535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-587
Description: oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-587
Description: oral suspension
Study: NCT04317625

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI scanning
Description: The patients whose PSA levels are between 2.5 and 4.0ng/ml will be recommended to mpMRI scanning at first but not biopsy or active surveillance.
Study: NCT01059071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: Escalating doses of DFMO in a 3 +3 cohort design.~DFMO at current cohort Dose Level orally each day for 21 day cycles~Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
Study: NCT03635853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug containing extract from cock's comb
Description: a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
Study: NCT04259606

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cassia Cinnamon
Description: Reddish - brown to light brown, typical sweet and aromatic free flowing powder.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Calcined magnesia
Description: White, odor, color and flavorless thin powder.
Study: NCT01957683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCLIPs™ Family of Products
Description: Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
Study: NCT00444795

Intervention type: DRUG
Intervention: Sunitinib malate
Description: Sunitinib : dosing not pre-determined

Intervention type: DRUG
Intervention: Sunitinib malate
Description: Sunitinib : dosing not pre-determined

Intervention type: DRUG
Intervention: sunitinib malate
Description: Sunitinib : dosing not pre-determined
Study: NCT03567005

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lenses
Description: Silicone hydrogel spherical contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lenses
Description: Silicone hydrogel spherical contact lenses
Study: NCT04890535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo oral suspension for TBAJ-587

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo oral suspension for TBAJ-587
Study: NCT02770651

Intervention type: DEVICE
Intervention: Everolimus-Eluting stent
Description: Everolimus-Eluting stent with bioabsorbable polymer

Intervention type: DEVICE
Intervention: Zotarolimus-Eluting stent
Description: Zotarolimus-Eluting stent with permanent polymer
Study: NCT03839342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: MEK inhibitor, 45mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: BRAF inhibitor, 450mg oral capsule
Study: NCT03820830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125 mg oral tablet taken daily for 3 years from randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard endocrine therapy
Description: Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard endocrine therapy
Description: Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
Study: NCT02346019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medial thighplasty with or without thigh liposuction
Description: Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
Study: NCT00262769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
Study: NCT03902145

Intervention type: OTHER
Intervention: Egg
Description: One egg per day for 6 months
Study: NCT01536535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Corticosteroid
Description: Treatment with IV Corticosteroid
Study: NCT02598986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Macronutrient supplementation
Description: adding of phosphorus, potassium and magnesium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Macronutrient supplementation
Description: adding of phosphorus, potassium and magnesium

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Macronutrient supplementation
Description: adding of phosphorus, potassium and magnesium
Study: NCT00783380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Description: Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subunit influenza vaccine
Description: Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
Study: NCT01473693

Intervention type: OTHER
Intervention: MRI Screening Form, MRI, Demographic / Medical Data form
Description: MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes.

Intervention type: OTHER
Intervention: MRI Screening Form, MRI. Demographic / Medical Data
Description: MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.~MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes
Study: NCT00825422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine / Placebo
Description: Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine / Placebo
Description: Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
Study: NCT01855217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: 1 mg/kg total BW based sugammadex reversal of deep block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: 1 mg/kg ideal BW based sugammadex reversal of deep block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9% NaCl
Study: NCT01534325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SD
Description: The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SD
Description: The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements.
Study: NCT03017430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxylamin
Study: NCT05021016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
Description: The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart.
Study: NCT03955913

Intervention type: OTHER
Intervention: Archival Tumor Tissue Sample
Description: Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue.
Study: NCT02497443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
Study: NCT00886743

Intervention type: DRUG
Group type: OTHER
Intervention: oprelvekin
Description: injection, 50 mg/kg, once daily
Study: NCT01416974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified T cells
Description: followed by consolidative therapy with the modified T cells in 3 planned cohorts.
Study: NCT00577980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
Study: NCT04240717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: The Patient Decision Aid is an interactive, web-based tool that provides information on advanced melanoma and its treatment options with a strong focus on immunotherapies (i.e. response to therapy, risk of side effects).
Study: NCT04116060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Nitrate
Description: Oral dietary nitrate supplementation with (0,12 mmol/kgBW sodium-nitrate)
Study: NCT01536535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Corticosteroid
Description: Treatment with IV Corticosteroid
Study: NCT04116060

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo Comparator: Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day)
Study: NCT04641325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention Group
Description: Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 8 weeks all patients will return for re-assessment.
Study: NCT03836950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
Description: The coil will be held tangentially to the skull at approximately 45º from the midline. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
Study: NCT01536535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroids
Description: Treatment with oral corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroids
Description: Treatment with oral corticosteroids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Therapies
Description: Anti-TNFα, Calcineurin inhibitor, Immunomodulator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Therapies
Description: Anti-TNFα, Calcineurin inhibitor, Immunomodulator
Study: NCT03836950

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
Description: The coil will be held tangentially to the skull at approximately 45º from the midline. The sham coil will not release any stimulation, but it will look, feel and sound like the real rTMS
Study: NCT03017430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxylamin
Study: NCT01536535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy
Description: Colectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy
Description: Colectomy
Study: NCT03017430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
Study: NCT01851174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion
Study: NCT03692338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will be asked to complete 3 x 30 minute exercise sessions each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will be asked to complete 3 x 30 minute exercise sessions each week.